Correlation between tissue PD-L1, TMB, and blood PD-L1, MSI biomarkers in patients with advanced-stage non-small cell lung cancer (NSCLC).

被引:0
|
作者
Nandimandalam, Sujitha
Sharma, Nitika
机构
[1] East Carolina Univ, Greenville, NC 27858 USA
[2] East Carolina Univ, Vidant Canc Care, Greenville, NC 27858 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
e21564
引用
收藏
页数:1
相关论文
共 50 条
  • [41] Association of PD-L1 expression with hotspot mutations in non-small cell lung cancer (NSCLC).
    Wan, Renping
    Zhang, Xiaoni
    Qu, Hongyue
    Li, Hui
    Li, Yingmei
    Xu, Mingyan
    Xiao, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] The relationship between clinicopathological parameters and PD-L1 expression level in advanced stage non-small cell lung cancer
    Gurbuz, Mustafa
    Dogan, Izzet
    Akkus, Erman
    Ozakinci, Hilal
    Tolunay, Pinar Kubilay
    Kalaci, Ender
    Baglan, Tolga
    Koksoy, Elif Berna
    Ceyhan, Koray
    Sak, Serpil Dizbay
    Aydiner, Adnan
    Demirkazik, Ahmet
    Utkan, Gungor
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (02): : 132 - 140
  • [43] Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy
    Dellepiane, C.
    Coco, S.
    Dal Bello, M. G.
    Rossi, G.
    Rijavec, E.
    Biello, F.
    Tagliamento, M.
    Longo, L.
    Mora, M.
    Anselmi, G.
    Alama, A.
    Bennicelli, E.
    Grossi, F.
    Zullo, L.
    Beshiri, K.
    Bottini, A.
    Pronzato, P.
    Genova, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S851 - S851
  • [44] Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
    Zhang, Jie
    Gao, Jing
    Li, Yanyan
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Chen, Xiaoling
    Han, Jindi
    Ma, Xiangjuan
    Tian, Guangming
    Wu, Di
    Shen, Lin
    Fang, Jian
    THORACIC CANCER, 2015, 6 (04) : 534 - 538
  • [45] PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer
    Ikeda, Seiichi
    Okamoto, Tatsuro
    Okano, Shinji
    Umemoto, Yuichiro
    Tagawa, Tetsuzo
    Morodomi, Yosuke
    Kohno, Mikihiro
    Shimamatsu, Shinichiro
    Kitahara, Hirokazu
    Suzuki, Yuzo
    Fujishita, Takatoshi
    Maehara, Yoshihiko
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) : 62 - 71
  • [46] Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
    Zhao, Yanjie
    Shi, Feng
    Zhou, Quan
    Li, Yuchen
    Wu, Jiangping
    Wang, Ruibin
    Song, Qingkun
    MEDICINE, 2020, 99 (45) : E23172
  • [47] Polymorphisms of the PD-L1 gene 3′-untranslated region are associated with the expression of PD-L1 in non-small cell lung cancer
    Ohhara, Yoshihito
    Tomaru, Utano
    Kinoshita, Ichiro
    Hatanaka, Kanako C.
    Noguchi, Takuro
    Hatanaka, Yutaka
    Amono, Toraji
    Matsuno, Yoshihiro
    Dosaka-Akita, Hirotoshi
    GENES CHROMOSOMES & CANCER, 2024, 63 (01):
  • [48] Serum immune checkpoint biomarkers as predictors of response to anti-PD-1/PD-L1 treatment in non-small cell lung cancer (NSCLC) patients
    Raza, A.
    Mohsin, R.
    Kanbour, A.
    Vijayakar, S.
    Philip, A.
    Tauro, M. A.
    Sherif, S.
    Merhi, M.
    Inchakalody, V.
    Gul, A. R. Zar
    Al Homsi, M. U.
    Dermime, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1380 - S1380
  • [49] Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
    Li, Lijun
    Pu, Haihong
    Zhang, Xiaoxin
    Guo, Xiaotian
    Li, Guangrui
    Zhang, Minghui
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 209
  • [50] Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients.
    Multani, Maneet
    Tarhoni, Imad
    Fughhi, Ibdihaj
    Basu, Sanjib
    Batus, Marta
    Bonomi, Philip D.
    Fidler, Mary J.
    Borgia, Jeffrey Allen
    Shah, Palmi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)